What is Dermacell? A dermal material, not stem cells

Dermacell is not a procedure that places living stem cells. It is a name for hADM (human acellular dermal matrix) made by removing cells from donated human skin. Even if it appears alongside stem cells in search results, the first point to confirm in consultation is whether cells are present in today’s sheet or syringe.

The materials this name can refer to

Dermacell, confirmed overseas as a product name, is a surgical sheet that places a remaining support structure of collagen and elastin onto the operative site after cells have been removed from donated dermis. The author of the paper that described this processing method is affiliated with the organization that handles that material. The clinic procedure name Dermacell is confirmed by the product name on the product documents used that day.

Name used	Material actually used	Form on the day
Dermacell	Matrix from donated dermis with the cells removed	Surgical sheet
Clinic procedure name Dermacell	Has a separate product name	Confirm in the product documents
SVF	Mixed cells collected from your own fat on the same day	Applied the same day after harvest

International societies describe SVF (stromal vascular fraction) obtained directly from fat as a different material from culture-expanded cells. SVF contains stromal cells together with vascular and immune-lineage cells. Among the authors of this joint statement are researchers with advisory or founding histories at cell-related companies. The pathway of collecting from fat continues in the SVF procedure guide, and human dermis minced for injection continues in the Re2O skin booster guide.

Sheet or injection: what splits on the day

Even when the same name is used, what is done that day diverges. If a sheet is placed, you hear about surgical anesthesia and how it is fixed; if it is injected, you hear about the layer and what is mixed in. PRF, which makes fibrin from your own blood, starts with a blood draw. The consent form records whether the material is donated dermis, your own fat, or your own blood. Materials prepared from blood are aligned with the PRF procedure guide.

Form	What is done that day	What to hear in advance
Surgical sheet	Covers or reinforces the site	Anesthesia, fixation method
Injection	Placed in portions into the planned skin layer	Injection layer, mixed ingredients
SVF	Fat is removed, then applied the same day	Harvest site, isolation method

Published human records are of sheets placed in breast reconstruction and chronic wounds. Figures for a facial-injection schedule sit outside the scope of those materials. Questions to ask before using donated dermis are collected in consulting on human tissue–derived materials. Procedure composition can be checked in the Dermacell procedure information.

Immediate reactions and when to contact

Injection sites are followed by temporary redness, swelling, and bruising. Records of this sheet in breast reconstruction include seroma and infection, and the paper that compiled those cases is a small consecutive observation. If warmth spreads or fever remains, or if shortness of breath or hives appear, contact the treating clinic immediately. Shared contact criteria are aligned with the procedure safety information.

Postpone saunas and vigorous exercise until the instructed period ends. When to resume washing and makeup follows the written instructions given that day.

Questions to ask as written in consultation

The quote and consent form should list the product name of the material placed today. The international society’s patient guide recommends leaving the material’s source, expected changes, and risks in writing. Asking the items below as written separates sheet, injection, and cell materials.

• □ What today’s product name is, and whether it is material with cells removed from donated dermis
• □ Whether it is a sheet or an injection, and if an injection, what is mixed in
• □ The anesthesia method, and symptoms that warrant immediate contact besides redness and swelling
• □ Where pregnancy and breastfeeding, active infection, anticoagulants and immunosuppressants, autoimmunity, and severe allergy are written down
• □ How far application and follow-up checks are included in the quote

An explanation that groups several sites under one stem-cell label and one material is treated as a warning sign in that same guide. The difference from cultured cells is in the guide to cells obtained from fat, and the pathway presented as a skin procedure is in the stem cell skin treatment guide.

Frequently asked questions

Q1. Is Dermacell a stem cell procedure?

It is material with the cells removed from donated dermis. Leaving that day’s product name in writing keeps it from being mixed with cells collected from fat or fibrin from blood.

Q2. Does it hurt?

At a sheet site, surgical anesthesia is discussed separately. At an injection site, the anesthesia method is confirmed to match the placement depth.

Q3. How many sessions?

A sheet is applied in a single surgical site, and a method that minces the material for injection sets the session count to match the product documents.

Q4. Can it be received together with SVF or PRF?

Because the materials differ, they are not all placed on the same day. After interval and order are set, the next appointment is booked. Where the three materials sit continues in the NovaStem, SVF, and PRF comparison.

Q5. Who postpones the schedule?

If there is pregnancy or breastfeeding, active infection, anticoagulant or immunosuppressant use, autoimmunity, or a severe allergy, the schedule is booked again. Also disclose medications you take and recent facial procedures in advance.

Results, duration, and suitability vary with individual skin condition, age, and lifestyle, and the same outcome cannot be guaranteed.

Procedures may cause temporary redness or swelling, and contraindications may apply, so please confirm these during your consultation.

This article is general information and does not replace individual medical care. Please confirm diagnosis and treatment suited to your condition during a consultation.

Sources

• Paper describing the process of removing cells from human dermis (PMID 25163609) — Verified scope: abstract and PMC full text. States that cells are removed with a non-denaturing detergent and nucleases, and that DNA removal exceeds 97% versus untreated dermis. Suggests use as a material for wound and soft-tissue reconstruction and reinforcement. Design limitations: a narrative review by authors affiliated with the processing organization; not a trial that measured the effect or safety of facial injection. Residual-amount figures appear only in the source tables. No Europe PMC retraction or expression of concern.
• Dermacell product information (processing organization) — Verified scope: product-page body (search results and quotations). Introduces it as human acellular dermal matrix, a sheet for soft-tissue reconstruction, stored at room temperature and used without rehydration. Design limitations: manufacturer page. Indication and effect of facial aesthetic injection sit outside this page’s scope.
• Consecutive cases of Dermacell sheets in tissue-expansion and implant breast reconstruction (PMID 25221385) — Verified scope: abstract and PMC full text. Of ten consecutive patients, eight completed reconstruction, and in two reconstruction ended because of chronic seroma and infection. Design limitations: small treatment observation; not facial-injection data. No author conflict-of-interest declaration on the abstract. No Europe PMC retraction or expression of concern.
• International society joint statement distinguishing adipose-derived SVF from cultured cells (PMID 23570660) — Verified scope: abstract and PMC full text. Places non-cultured SVF as a mixed cell layer after mature adipocytes are filtered out, and distinguishes it from culture-expanded cells. States that the composition includes stromal cells, vascular endothelial cells, lymphocytes, macrophages, and others. Design limitations: a nomenclature document, not an evaluation of clinical effect or safety. Among the authors are those with advisory, founding, or patent histories at cell-related companies. No Europe PMC retraction or expression of concern.
• International society patient guide to stem cell procedures (February 2024 edition) — Verified scope: guide PDF body. Established treatments are transplants for blood and immune diseases, including blood cancers. Recommends confirming the material’s source and preparation method in writing, and presents an explanation that one cell type treats several sites as a warning sign. Design limitations: not data that measured the effect or incidence of individual Dermacell or hADM products.

Related reading

• Dermacell procedure information
• Re2O skin booster treatment process
• SVF procedure guide
• PRF procedure guide
• Consulting on human tissue–derived materials
• Stem cell skin treatment guide
• Cells from fat versus cultured cells
• NovaStem, SVF, and PRF comparison
• Procedure safety information